Wednesday, 1 December 2021

BioLargo Signs Manufacturer’s Representative Agreement with ICS Group for its Innovative Water Treatment Technologies

Westminster, CA – December 1, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced it has signed a manufacturer’s representative agreement with the ICS Group, a premier manufacturer’s representative company that has provided innovative wastewater, energy management, and renewable energy technology solutions to municipal and industrial clients, primarily in the Midwestern United States, since 2009. As this is the first manufacturer’s representative for BioLargo’s innovative water treatment technologies, this represents an important step toward building a commercial network for their sale and distribution.

ICS Group has been tasked to sell BioLargo’s two proprietary water treatment technologies, the Advanced Oxidation System (AOS) energy-efficient wastewater disinfection, micropollutant removal, and water reuse technology, and the Aqueous Electrostatic Concentrator (AEC) technology for affordable, low-waste treatment of PFAS-contaminated water, as well as other water and wastewater treatment equipment that BioLargo offers as an authorized reseller of other manufacturers. The ICS Group will also sell BioLargo’s PFAS Testing Program service, which offers fast and affordable testing of clients’ PFAS-contaminated water for the purposes of treatment system optimization, and CupriDyne Clean, the company’s patented odor and volatile organic compound (VOC) control product.

Paul Nygaard, President of ICS Group, said, “We specialize in innovative water and wastewater process technologies. We always strive to bring cutting edge technologies to the market that help our clients achieve challenging treatment objectives. BioLargo’s unique technology platforms definitely bring that capability to our treatment solutions.”   

“ICS Group has a reputation of outstanding customer service, making them the perfect choice to be our first manufacturer’s representative for our technologies. They’re also known for taking on new and innovative technologies that address unmet needs in the water treatment marketplace,” said Tonya Chandler, BioLargo’s Director of Strategic Marketing and Business Development. “We intend to add more sales representatives soon and hope they will be as great a fit as the ICS Group to our values.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Tuesday, 30 November 2021

BioLargo Strategic Partnership with Ikigai to Launch New Consumer Product

Direct to Consumer Test Marketing is Successful

Westminster, CA – November 30, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that it had received a “go decision” from its strategic partner, Ikigai Holdings, LLC, following positive results from the test-marketing phase of a new pet odor control product based on BioLargo’s proprietary technology, branded “POOPH”. The “go decision” indicates Ikigai’s intent to expand television advertising with the goal to launch the product into big-box retailers, and formalizes their exclusive license to the product.

Ikigai Holdings, LLC is comprised of veteran consumer product executives with experience launching and growing multiple blockbuster consumer products. Ikigai developed the “POOPH” brand, created television commercials and other advertising content, and then conducted a television direct-response test marketing campaign to assess the probability that the product would be a commercial success.

Jane Pak, Ikigai CEO, commented, “Early feedback from the test marketing of the POOPH product has been phenomenal. We have placed our initial purchase orders to support an expanded marketing campaign that will begin right after Christmas to gather additional data which will be instrumental in supporting accelerated consumer sales and establishing a strong transition from direct-to-consumer into retail. We are thrilled to see validation that POOPH can disrupt the highly established category of pet odor control products, and with these results, we are already thinking about more products based on BioLargo’s technology.”

BioLargo CEO Dennis P. Calvert commented, “Ikigai will purchase the POOPH products from us, and in addition, we receive a royalty on sales. They will finance and manage product roll-out, distribution, and marketing. We are excited about the potential for this partnership to create significant new revenue for both partners. The team at Ikigai is amazing!”

  

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

Monday, 15 November 2021

BioLargo’s Third Quarterly Report for 2021 Details Progress of PFAS Technology Commercialization and Ongoing Partnerships













Westminster, CA – November 16, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its latest Quarterly Report on Form 10-Q with the SEC yesterday (www.biolargo.com/sec-filings). The company has summarized some of the most important points from the report below.

The company is holding an investor webcast on Wednesday, November 17, 2021, at 8:00 am Pacific / 11:00 am Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/43712   

Dennis P. Calvert, President and CEO of BioLargo said, “In this quarter, our engineering group broke its all-time revenue record. We began the first step of the multi-phase commercial launch of our PFAS treatment technology and confirmed the technology works with real client-provided water, achieving results that meet government standards. Our work at the Montreal wastewater treatment plant proved that our other water treatment technology, the AOS, is highly effective at removing pharmaceuticals from wastewater compared to existing technologies. Our consolidated revenue grew, and we shrank our net loss.”

He continued, “The hard work we’ve done to prepare to launch products with Garratt-Callahan is paying off. We will be doing commercial testing with water from multiple prospective Garratt-Callahan customers in the coming weeks. We’re on track to secure first customer orders for this product in the first quarter of 2022.”

Financial highlights from the 10-Q:

  • Consolidated revenue for the three months ended September 30, 2021, was $712,000, a 7% increase compared to the prior year’s period. Revenue generated by BioLargo’s engineering division increased by 73% compared to last year’s period, and 92% as compared with the second quarter of 2021.
  • The company’s net loss during the quarter was reduced to $1.3 million, down from $2.1 million in the same period of the prior year. The improvement in the company’s net loss is due in large part to a significant reduction in interest expenses due to retired debt over the past year.

Commercial, operational, and R&D highlights:

  • First PFAS testing successful – testing of water provided by the company’s first prospective PFAS treatment client, a large municipality in southern California, has confirmed that BioLargo’s PFAS treatment technology can remove all PFAS compounds of regulatory interest to below State and Federal standards. Additional testing to optimize the AEC underway. Testing with our second prospective client’s water is slated to begin next week.
  • Garratt-Callahan prototype unit completed – as part of BioLargo’s partnership with the water treatment company Garratt-Callahan, BioLargo has just finished building a full-scale prototype unit of their patented “minimal liquid discharge” system for testing on client-provided water. The technology is designed to reduce industrial wastewater discharge and fees associated with discharge. BioLargo engineers will be testing the system’s performance soon, and management targets first sales in the early 2022.
  • Engineers break revenue record – BioLargo’s engineering group’s quarter-over-quarter revenue grew by 92% in Q3, having completed over half the work for the $1.2 million worth of engineering projects announced in June of 2021, the remainder of which is expected to complete in the next six months.
  • 3-year exclusive chemistry supply contract – BioLargo’s subsidiary ONM Environmental secured an exclusive three-year CupriDyne Clean supply contract with a large municipality in Southern California.
  • TV test marketing shows promising results – a quote from Ikigai Holdings President Jane Pak on the new pet odor product based on BioLargo’s technology: “The Ikigai team is pleased to see the product get a positive response early in the market testing period. The next three weeks of media placement will be critical to predicting probability of volume and velocity, but in our first week of placement we are already seeing some very promising results.”
  • AOS pilot confirms performance – the AOS pilot project in Montreal, Quebec, has confirmed that the AOS is highly effective at removing pharmaceutical micropollutants from municipal wastewater in a real-world setting, faster and using less electricity than major incumbent technologies, making it an attractive product for municipal wastewater treatment customers. A video about this pilot is available here: https://biolargo.blogspot.com/2021/09/biolargo-aos-water-treatment-technology.html
  • Peer-reviewed paper confirms AOS breakthrough – a peer-reviewed scientific paper was published confirming that the AOS generates highly energetic iodine molecules, helping explain why the AOS is a powerful, efficient, and novel water treatment technology. The article, and a summary thereof, can be accessed here: https://biolargo.blogspot.com/2021/09/peer-reviewed-paper-explains.html

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Q3 2021 Earnings Results Webcast and Conference Call on Wednesday, November 17, 2021 - 11:00 AM Eastern Time

Westminster, CA – November 15, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Wednesday, November 17, 2021, at 8:00 am PST / 11:00 am EST. The webcast and conference call, which is open to the public, will be held to review the company’s financial results, discuss recent commercial milestones, and conduct a question-and-answer session.

The webcast and teleconference replay will be made available on the Investor Relations section of BioLargo’s website at biolargo.com/investor-relations. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time to register, download, and install any necessary audio video software.

 

To participate in the live webcast and teleconference:

Webcast Link:

https://www.webcaster4.com/Webcast/Page/2448/43712

Teleconference Domestic:

888-506-0062

Teleconference International:

973-528-0011

 

To watch or listen to a replay of the webcast or teleconference:

 

Webcast Replay Expiration:

Wednesday, November 16, 2022

Teleconference Replay Expiration:

Tuesday, December 1, 2022

Teleconference Replay Domestic:

877-481-4010

Teleconference Replay International:

919-882-2331

Replay Passcode:

43712

 

 About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

 

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

Friday, 12 November 2021

Opportunity Meets Preparation: Water Online Interview with BioLargo CEO at WEFTEC

 Source: Water Online

The Water Online editorial staff sat down with Dennis Calvert, CEO of BioLargo, at WEFTEC 2021 to discuss BioLargo’s PFAS solutions, the state of the water industry, and their AOS water treatment technology.

Listen the full interview here: https://www.wateronline.com/doc/opportunity-meets-preparation-0001



Monday, 25 October 2021

Stock Day Podcast: BioLargo Discusses Ikigai Partnership and PFAS Treatment Technology with The Stock Day Podcast (BLGO)

Phoenix, Arizona–(Newsfile Corp. – October 25, 2021) – The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), a company that invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, and infection control. President and CEO of BioLargo Dennis P. Calvert, joined Stock Day host Everett Jolly for an interview.

Jolly began by asking about the company’s innovative water treatment technology for per- and polyfluoroalkyl substances (PFAS), a class of water contaminants of escalating human health and regulatory concern. Calvert explained that this technology has unprecedented performance compared to existing technologies. “We are at the forefront of presenting a technical innovation that has a chance to be the industry leader,” said Calvert. “This is a solution that demands global reach,” he added, noting that the company intends on licensing the technology to well-established water treatment distributors and plans to launch the technology in 2022.

Calvert then discussed the company’s odor and VOC (volatile organic compound) control solutions, which are at the center of a new consumer product partnership with Ikigai Holdings, LLC. “We’re going to keep the market posted as that product goes into test marketing,” said Calvert. The company will manufacture the new consumer odor control product (based on an existing BioLargo IP), and Ikigai Holdings will finance and manage its roll-out, distribution, and marketing.

To close the interview, Calvert encouraged listeners and shareholders to check out the company’s recent letter to stockholders and keep up-to-date on their current and upcoming projects as they continue to develop and commercialize their solutions.

To hear the entire interview, follow the link to the podcast here: https://audioboom.com/posts/7966717-biolargo-discusses-ikigai-partnership-and-pfas-treatment-technology-with-the-stock-day-podcast.

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB: BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

About The “Stock Day” Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:

Stock Day Media

(602) 821-1102

Wednesday, 20 October 2021

Biden Administration and EPA Unveil Far-Reaching Plans to Tackle PFAS Contamination

Over the past year, the Biden Administration and the Environmental Protection Agency have begun the process of regulating per- and polyfluoroalkyl substances (PFAS) in drinking water and creating new rules on discharge of PFAS chemicals from industrial facilities. On October 18, the EPA and the White House both made major announcements of plans to reduce the impact of these toxic chemicals, providing greater clarity on the evolving regulatory landscape surrounding PFAS over the coming years.

First, the EPA announced their “PFAS Strategic Roadmap” this week, outlining the agency’s multifaceted strategy to regulate and remediate PFAS throughout over the next three years and beyond. The roadmap, found here, describes the anticipated timeline for various aspects of regulatory action on PFAS chemicals. The EPA intends to release more details about each aspect of their roadmap in a series of webinars planned over the next few weeks.

Some of the highlights of the EPA’s roadmap include:

  • Nationwide monitoring of PFAS in drinking water, aimed for the Fall of 2021.
  • A proposal to designate certain PFAS chemicals as hazardous chemicals under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA; a.k.a. the “Superfund”), which will provide federal funding for cleanup of PFAS-contaminated sites and increase the handling requirements for PFAS-contaminated materials.
  • The establishment of national drinking water regulations for two of the most common PFAS chemicals, PFOA and PFOS, that would set “enforceable limits” and necessitate that all public water supplies be monitored. This rulemaking is targeted for Fall of 2022, with a final rule made Fall of 2023.
  • Develop rules surrounding monitoring of PFAS-containing emissions from industrial facilities (aimed for Fall of 2022).
  • Plans to review new and existing PFAS chemicals under the Toxic Substances Control Act
  • Evaluate and assist in the development of new technologies that can help remove PFAS from the environment, including site cleanup and remediation technologies and water treatment technologies.

The same day as the EPA’s roadmap was released, the Biden-Harris Administration announced their formal plan to combat PFAS contamination across the country. In their press release, they promised “accelerated efforts to protect Americans from per- and polyfluoroalkyl substances (PFAS)” through a concerted effort by eight federal agencies to mitigate PFAS from different angles.

The first and most wide-reaching part of their plan is the EPA’s new PFAS roadmap, detailed above. The Department of Defense is another agency taking swift and concrete action. The DOD is responsible for more than 700 potentially PFAS-contaminated sites around the country such as air force bases and National Guard locations where PFAS-containing fire-fighting foam was used. The DOD is presently conducting cleanup assessments to plan for the remediation of all sites where PFAS contamination is found. The agency is also funding over $150 million to help develop PFAS remediation solutions.

Other federal agencies who will be taking action as part of the federal government’s PFAS response include the Food and Drug Administration, the Department of Agriculture, the Department of Homeland Security, the Department of Health and Human Services, the Federal Aviation Administration, and the White House’s Council on Environmental Quality (CEQ). These agencies are engaged in initiatives ranging from funding scientific research on the health effects of the broader range of PFAS chemicals, to programs to support first responders affected by PFAS-related health problems, to efforts to quantify and mitigate the presence of PFAS in food products and livestock animals.

This week’s announcements bring much-awaited clarity about the Federal government’s plans to create a regulatory framework surrounding PFAS. Municipal governments, water agencies, and industrial companies need that clarity in order to make informed decisions on what treatment and mitigation systems they should implement to safeguard their water or wastewater into the future. The EPA’s new roadmap doesn’t provide all the answers to questions about the evolving regulatory landscape, but it does give industry stakeholders a solid idea of when different regulatory actions are likely to happen, and what their impact might be.

In particular, the decision to move ahead with designating certain PFAS as hazardous chemicals under CERCLA is likely to have substantial effects on the way PFAS-contaminated site and waterways are remediated. Making PFAS-contaminated sites eligible for Superfund funding may accelerate the pace of treating those sites, especially in light of the high capital cost of some PFAS cleanup projects. The CERCLA proposal may also make handling PFAS-laden waste, such as that waste generated by PFAS water treatment, a more complex issue, which will probably encourage customers to choose PFAS treatment options that generate less waste.

About BioLargo’s PFAS Treatment Technology

BioLargo’s PFAS water treatment technology was developed from the ground-up to be the sustainable, low-waste solution for affordable PFAS removal. Called the Aqueous Electrostatic Concentrator (AEC), it works by separating PFAS compounds in an electric field and forcing them onto specialized, compact, proprietary membranes, which can later be disposed of easily and safely.

The AEC removes more than 99% of PFAS from water in continuous flow, at energy costs as low as 30 cents per 1,000 gallons.

Compared to carbon-based filtration, the most common PFAS removal system, the AEC generates approximately 1/1000 the amount of PFAS-laden waste by weight, has a significantly lower carbon footprint, produces higher purity water, and is more compact. With regulations around the U.S. tightening surrounding the handling of PFAS-laden waste, this makes the AEC a more practical solution for PFAS water treatment.

You can learn more about the BioLargo AEC, as well as BioLargo’s PFAS water testing program, at www.biolargoengineering.com/biolargo-aec.